A Multicenter, Open-Label, Flexible Dose Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures
Phase of Trial: Phase II
Latest Information Update: 06 Feb 2019
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors INSYS Therapeutics, Inc
- 19 Jan 2018 Status changed from not yet recruiting to recruiting.
- 04 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Jan 2018.
- 30 Nov 2017 New trial record